• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » HeartWare stock gains 4.5% as analysts predict FDA approval ahead of panel meeting

HeartWare stock gains 4.5% as analysts predict FDA approval ahead of panel meeting

April 23, 2012 By MassDevice staff

HeartWare logo

Despite FDA concerns, analysts expect a positive vote for HeartWare International‘s (NSDQ:HTWR) HVAD ventricular assist system as a bridge to transplant for patients with end-stage heart failure.

Analysts at Leerink Swann wrote that the FDA panel’s warnings "were not as bad as feared" and Barclays upgraded HeartWare shares to an "overweight" rating, maintaining a price target of $80 per share.

The news gave HTWR shares a 4.5% bump to $70.14 as of about 1:45 p.m. today. HeartWare’s HVAD heart pump will get the full FDA treatment this Wednesday.

"While there are a number of ‘panel risks’ that will come into focus at HTWR’s 4/25 FDA meeting (which we believe pressured shares over the last 2 months), we believe the most probable outcome is that HTWR’s HVAD device receives a recommendation for approval," Barclays analyst Matthew Taylor wrote in a note to investors. "On that basis, we think that the stock will work in the near term and are upgrading shares in anticipation of a favorable panel vote."

Members of the FDA’s circulatory systems advisory panel added that clinical trials for the HVAD system, the only heart pump trials to use a registry of patients as a control arm, may have been biased in favor of HeartWare’s device, Reuters reported.

"Though the day is likely to be tough, we continue to believe that HTWR will successfully convince the panel of HVAD’s overall benefit/risk profile," Leerink Swann analysts wrote.

The panel also noted that 8% of HVAD recipients in the clinical trials had an ischemic stroke, compared to 5-6% in trials for other pumps.

Overall, the HVAD studies reported a survival rate of more than 90% out to 180 days for the 250 studied patients using the device as a bridge to heart transplant, but also found a 6.4% rate of thrombosis and a 8.4% rate of thrombosis plus device exchange. That rate is "significantly higher" than for rival heart pump maker Thoratec’s (NSDQ:THOR) HeartMate II, which won FDA approval in 2008 and has enjoyed a corner on the market for bridge-to-transplant heart pumps for patients with heart failure since then, Leerink analysts noted.

"We believe the overall success of the pivotal trial and FDA’s desire to have an alternative pump on the market to Thoratec’s HeartMate II will result in approval of the HVAD later this year," Wells Fargo analyst Larry Biegelsen wrote.

"We expect a positive panel recommendation with potential conditions to approval, i.e. inclusion of thrombosis and stroke data on the label and extensive post-approval studies to monitor serious adverse events," the Leerink analysts wrote.

Filed Under: Cardiac Implants, Food & Drug Administration (FDA), News Well, Wall Street Beat Tagged With: Barclay's, Cardiac Rhythm Management, Clinical Trials, HeartWare International Inc., Leerink Partners, Thoratec Corp., Wells Fargo

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy